Yesterday Philip Low of NeuroVigil spoke at TEDMED and demonstrated the amazing iBrain technology his firm developed to monitor and interpret EEG signals. Today NeuroVigil announced a partnership with Roche that would provide the iBrain for use in outpatient clinical trials. We were lucky to be able to grab a few minutes of Philip’s time immediately after the announcement to explain what this news means to our audience:
Press release: NeuroVigil and Roche Launch Personalized Neurodiagnostics Initiative for Enabling Preventive Treatment of CNS Disorders …
